null

SMILES CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(C)c1ncnc2[nH]ccc12

InChI Key

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 185700   

TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 9.53nMpH: 7.4Assay Description:Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2CC0ZF7US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 17.5nMpH: 7.4Assay Description:Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2CC0ZF7US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 95.1nMpH: 7.4Assay Description:Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2CC0ZF7US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 75.1nMpH: 7.4Assay Description:Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2CC0ZF7US Patent
TargetTyrosine-protein kinase JAK1 [852-1142](Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 9.53nMpH: 7.4Assay Description:Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2VD6X90US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 3.40nMMore data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2P55RMMUS Patent
TargetTyrosine-protein kinase JAK3 [781-1124](Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 95.1nMpH: 7.4Assay Description:Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2VD6X90US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [870-1187](Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 75.1nMpH: 7.4Assay Description:Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2VD6X90US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 18nMAssay Description:Inhibition of human recombinant JAK2 (808 to 1132 residues) by Z-Lyte assayMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2B27ZSZPubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 10nMAssay Description:Inhibition of human recombinant JAK1 (852 to 1142 residues) by Z-Lyte assayMore data for this Ligand-Target Pair
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2B27ZSZPubMed
TargetTyrosine-protein kinase JAK2 [809-1153](Homo sapiens (Human))
Zoetis Services LLC

US Patent
LigandPNGBDBM185700(US10875847, Compound Oclacitinib | US9161939, 1a |...)copy SMILES
Affinity DataIC50: 17.5nMpH: 7.4Assay Description:Methods: A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK-2 and JAK-3) or the IRS-1 peptide (JAK-1 and Tyk...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2VD6X90US Patent